argenx (ARGX) Q1 2026 earnings summary

Executive summary

• Achieved $1.3 billion in global product net sales for Q1 2026, up 63% year-over-year, with strong commercial momentum in MG and CIDP and expanding prescriber base and earlier-line use.

• Operating profit rose to $394 million, up 183% year-over-year, with net profit at $366 million, up 116% from the prior year.

• Vision 2030 targets 50,000 patients on treatment, 10 labeled indications, and five late-stage molecules by decade's end.

• CEO transition to Karen Massey and appointment of Tim Van Hauwermeiren as Board Chair, with no change in strategic direction.

• Expanded global presence with a new affiliate in China and continued investment in next-generation FcRn assets.

Financial highlights

• Q1 2026 product net sales reached $1.3 billion, up 63% year-over-year; U.S. sales were $1.1 billion, with Japan and Rest of World seeing 111% and 99% growth, respectively.

• Operating profit was $394 million with a 30% margin, and net profit for Q1 2026 was $366 million.

• SG&A expenses decreased 17% quarter-over-quarter; R&D expenses were $443 million, and SG&A expenses were $355 million for Q1 2026.

• Cash, cash equivalents, and current financial assets totaled $4.9 billion at quarter-end, up from $4.4 billion at year-end 2025.

• Basic EPS increased to $5.90 from $2.78 year-over-year.

Outlook and guidance

• Full-year expectations for VYVGART remain unchanged, with growth trajectory consistent with prior years and Vision 2030 targeting 50,000 patients and 10 labeled indications.

• Anticipated label expansions in MG (seronegative, ocular, pediatric) and upcoming PDUFA date for seronegative MG on May 10, 2026.

• Key upcoming catalysts include Phase III readouts in autoimmune myositis (Q3 2026), MMN (Q4 2026), and Sjögren's (H2 2027), with empasiprubart as a key upcoming launch.

• Margin expansion expected to continue quarterly and annually.

• VYVGART SC autoinjector launch planned for 2027 for all approved indications.